论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
关于 0.01% 阿托品滴眼液联合角膜塑形镜治疗青少年近视的疗效及炎症调节作用的研究
Authors Wang H, Piao J, Yoo G, Li D, Liu J , In-chul J
Received 2 June 2025
Accepted for publication 25 August 2025
Published 2 September 2025 Volume 2025:18 Pages 12077—12087
DOI https://doi.org/10.2147/JIR.S539831
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Justin Jacob
Hui Wang,1,2 Junfeng Piao,3 Geunchang Yoo,2 Danqi Li,1 Jun Liu,1 Jeon In-chul2
1Ophthalmology Center, Changzhi People’s Hospital, Changzhi Medical College, Changzhi, People’s Republic of China; 2Department of Optometry, School of Health and Welfare, Dongshin University, Naju, Korea; 3Ophthalmology Department, Guro Hospital, Korea University, Seoul, Korea
Correspondence: Jun Liu, Email uoo3776@163.com Jeon In-chul, Email icjeon@dsu.ac.kr
Objective: To evaluate the therapeutic efficacy and inflammatory modulatory effects of combined 0.01% atropine eye drops and orthokeratology (OK) lenses in controlling myopia progression among adolescent patients.
Methods: This retrospective study analyzed clinical data from 90 adolescent patients (90 eyes) with myopia treated from April 2021 to June 2023. Patients were divided into two groups: control group (n=45, treated with OK lenses alone) and observation group (n=45, treated with OK lenses combined with 0.01% atropine). Baseline and 1-year post-treatment measurements included refractive status, axial length (AL), corneal parameters, ocular surface indices, tear film stability, endothelial cell morphology, inflammatory cytokine levels in tears, and incidence of adverse events.
Results: After 1 year, both groups showed myopic progression, but the observation group exhibited significantly less axial elongation (0.12 ± 0.08 mm vs 0.21 ± 0.09 mm; p < 0.001) and smaller increases in refractive error (p < 0.001). Corneal curvature and central corneal thickness were also significantly lower in the observation group (p < 0.05). The pupil diameter increased more in the observation group (p = 0.002), consistent with atropine’s pharmacologic effect. Ocular surface damage was less severe, with lower OSDI (p = 0.002) and staining scores (p < 0.001). Tear film stability was better preserved, as reflected by higher NIBUT and TBUT values (p < 0.05). No significant differences in endothelial cell density or hexagonality were observed (p > 0.6). Tear cytokine levels (IL-1β, IL-6, TNF-α) increased in both groups but were significantly lower in the observation group (all p < 0.01). The incidence of adverse reactions was low and comparable between groups (p = 0.235), with no severe events reported.
Conclusion: The combination of 0.01% atropine eye drops with orthokeratology lenses is more effective than orthokeratology alone in controlling myopia progression and mitigating ocular surface inflammation in adolescents, without increasing adverse effects.
Keywords: adolescents, myopia, orthokeratology lenses, 0.01% atropine eye drops, inflammatory response, effect